COMPLEMENT PROPHYLACTIQUE A BASE DE 17A-ACYLOXY-6 METHYLPREGNA-4,6-DIENE-3,20-DIONE

COMPLEMENT PROPHYLACTIQUE A BASE DE 17A-ACYLOXY-6 METHYLPREGNA-4,6-DIENE-3,20-DIONE

The use of a 17 alpha-acyloxy-6-methyl pregna-4,6-dien-3,20 dione (I) in which the acyl group has up to 10C atoms, as a therapeutic agent for oral or parenteral admin. to patients or animals who have undergone mastectomy following breast cancer, is new. The admin. is continued until there is no furt...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
1. Verfasser: MARTIN O. GREANEY ET MERRITT R. CALLANTINE
Format: Patent
Sprache:fre
Schlagworte:
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
STEROIDS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The use of a 17 alpha-acyloxy-6-methyl pregna-4,6-dien-3,20 dione (I) in which the acyl group has up to 10C atoms, as a therapeutic agent for oral or parenteral admin. to patients or animals who have undergone mastectomy following breast cancer, is new. The admin. is continued until there is no further risk of matastatic transmission or recurrence of the cancer. Better activity than known therapeutic agents, and absence of toxicity. (I) is preferably given as soon after the mastectomy as possible, and it is continued for 2-5 years. The daily dosage is 40-800 mg preferably 160-320 mg, given in 2-8 doses, pref. 4. (I) may be given with other active components, such as digitalin, insulin, non-steroidal anti-inflammatories, and analgesics.